Cannara Biotech Stock Technical Analysis
| LOVFF Stock | USD 1.40 0.03 2.19% |
As of the 10th of February, Cannara Biotech shows the Risk Adjusted Performance of 0.0908, mean deviation of 1.97, and Downside Deviation of 3.19. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cannara Biotech, as well as the relationship between them. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Cannara Biotech, which can be compared to its peers. Please confirm Cannara Biotech treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Cannara Biotech is priced correctly, providing market reflects its regular price of 1.4 per share. Please also double-check Cannara Biotech total risk alpha, which is currently at (0.03) to validate the company can sustain itself at a future point.
Cannara Biotech Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Cannara, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to CannaraCannara |
Cannara Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cannara Biotech's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cannara Biotech.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Cannara Biotech on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Cannara Biotech or generate 0.0% return on investment in Cannara Biotech over 90 days. Cannara Biotech is related to or competes with Grown Rogue, Shield Therapeutics, HLS Therapeutics, Orexo AB, Biosyent, Orexo AB, and Kintor Pharmaceutical. Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabi... More
Cannara Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cannara Biotech's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cannara Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.19 | |||
| Information Ratio | 0.07 | |||
| Maximum Drawdown | 15.5 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 6.77 |
Cannara Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannara Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cannara Biotech's standard deviation. In reality, there are many statistical measures that can use Cannara Biotech historical prices to predict the future Cannara Biotech's volatility.| Risk Adjusted Performance | 0.0908 | |||
| Jensen Alpha | 0.347 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.0631 | |||
| Treynor Ratio | (0.45) |
Cannara Biotech February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0908 | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 1.97 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 3.19 | |||
| Coefficient Of Variation | 959.23 | |||
| Standard Deviation | 2.87 | |||
| Variance | 8.26 | |||
| Information Ratio | 0.07 | |||
| Jensen Alpha | 0.347 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.0631 | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 15.5 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 6.77 | |||
| Downside Variance | 10.2 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (3.54) | |||
| Skewness | 0.4349 | |||
| Kurtosis | 1.39 |
Cannara Biotech Backtested Returns
At this point, Cannara Biotech is dangerous. Cannara Biotech secures Sharpe Ratio (or Efficiency) of 0.0691, which signifies that the company had a 0.0691 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Cannara Biotech, which you can use to evaluate the volatility of the firm. Please confirm Cannara Biotech's Mean Deviation of 1.97, risk adjusted performance of 0.0908, and Downside Deviation of 3.19 to double-check if the risk estimate we provide is consistent with the expected return of 0.19%. Cannara Biotech has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cannara Biotech are expected to decrease at a much lower rate. During the bear market, Cannara Biotech is likely to outperform the market. Cannara Biotech right now shows a risk of 2.79%. Please confirm Cannara Biotech downside variance, and the relationship between the treynor ratio and kurtosis , to decide if Cannara Biotech will be following its price patterns.
Auto-correlation | -0.14 |
Insignificant reverse predictability
Cannara Biotech has insignificant reverse predictability. Overlapping area represents the amount of predictability between Cannara Biotech time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cannara Biotech price movement. The serial correlation of -0.14 indicates that less than 14.0% of current Cannara Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.14 | |
| Spearman Rank Test | 0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Cannara Biotech technical otc stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, otc market cycles, or different charting patterns.
Cannara Biotech Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for Cannara Biotech across different markets.
About Cannara Biotech Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Cannara Biotech on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Cannara Biotech based on its technical analysis. In general, a bottom-up approach, as applied to this otc stock, focuses on Cannara Biotech price pattern first instead of the macroeconomic environment surrounding Cannara Biotech. By analyzing Cannara Biotech's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Cannara Biotech's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Cannara Biotech specific price patterns or momentum indicators. Please read more on our technical analysis page.
Cannara Biotech February 10, 2026 Technical Indicators
Most technical analysis of Cannara help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Cannara from various momentum indicators to cycle indicators. When you analyze Cannara charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0908 | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 1.97 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 3.19 | |||
| Coefficient Of Variation | 959.23 | |||
| Standard Deviation | 2.87 | |||
| Variance | 8.26 | |||
| Information Ratio | 0.07 | |||
| Jensen Alpha | 0.347 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.0631 | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 15.5 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 6.77 | |||
| Downside Variance | 10.2 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (3.54) | |||
| Skewness | 0.4349 | |||
| Kurtosis | 1.39 |
Cannara Biotech February 10, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Cannara stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | Huge | ||
| Rate Of Daily Change | 1.02 | ||
| Day Median Price | 1.40 | ||
| Day Typical Price | 1.40 | ||
| Price Action Indicator | 0.01 |
Complementary Tools for Cannara OTC Stock analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |